Skip to main content
. Author manuscript; available in PMC: 2021 Nov 1.
Published in final edited form as: Ann Oncol. 2020 Aug 13;31(11):1518–1525. doi: 10.1016/j.annonc.2020.08.2064

Table 3.

Adverse events occurring in ≥ 20% of patients

Toxicity Cisplatin (n = 72) Paclitaxel (n = 68)
Any Grade Grade 3/4 Any Grade Grade 3/4
Nausea 57 (76%) 1 (1%) 31 (43%) 0 (0%)
Fatigue 55 (73%) 0 (0%) 52 (72%) 0 (0%)
Neutrophil count decreased 40 (53%) 1 (1%) 26 (36%) 0 (0%)
Anemia 34 (45%) 1 (1%) 38 (53%) 0 (0%)
Constipation 31 (41%) 0 (0%) 19 (26%) 0 (0%)
White blood cell count decreased 29 (39%) 0 (0%) 25 (35%) 0 (0%)
Tinnitus 26 (35%) 0 (0%) 1 (1%) 0 (0%)
Hypomagnesemia 23 (31%) 0 (0%) 5 (7%) 0 (0%)
Headache 19 (25%) 0 (0%) 25 (35%) 0 (0%)
Hypertension 19 (25%) 2 (3%) 22 (31%) 0 (0%)
Anxiety 17 (23%) 0 (0%) 24 (33%) 0 (0%)
Diarrhea 16 (21%) 1 (1%) 23 (32%) 0 (0%)
Platelet count decreased 16 (21%) 0 (0%) 3 (4%) 0 (0%)
Insomnia 15 (20%) 0 (0%) 24 (33%) 0 (0%)
Dysgeusia 11 (15%) 0 (0%) 15 (21%) 0 (0%)
Peripheral sensory neuropathy 10 (13%) 0 (0%) 41 (57%) 0 (0%)
Alanine aminotransferase increased 6 (8%) 0 (0%) 16 (22%) 0 (0%)